Drugs / CSL689
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02470871 | Jul 2015 → Jul 2016 | congenital factor VII deficiency | CSL Behring | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02484638 | Jul 2015 → Mar 2018 | hemophilia A, hemophilia B | CSL Behring | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-07-03 | CSL Behring | Results CSL Behring Presents Phase I Results From Study of Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers csl.com ↗
03 Jul 2013 CSL Behring today presented Phase I data of their recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) in healthy volunteers at the International Society on Thrombosis and Haemostasis (ISTH) congress in Amsterdam. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL689 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02484638 ↗ |
| Known as | rVIIa-FP | “Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a...” NCT02470871 ↗1“The purpose of this study is to investigate the pharmacokinetics (PK), efficacy, and safety of rVIIa-FP (CSL689).” NCT02484638 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP)” NCT02470871 ↗ |
| Route | Other | “CSL689 injection” NCT02470871 ↗ |